Evidence map›Paper›PMID 40855317›Full record

ArticleGenome medicine2025

Replication-associated mechanisms contribute to an increased CpG > TpG mutation burden in mismatch repair-deficient cancers.

Joseph C Ward, Ignacio Soriano, Steve Thorn, Juan Fernández-Tajes, Kitty Sherwood, Güler Gül, Joost Scheffers, Anna Frangou, Ben Kinnersley, Ioannis Kafetzopoulos and 6 more

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Joseph C WardDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.ORCID 0009-0000-8319-6464
Ignacio SorianoDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.ORCID 0000-0002-7928-3511
Steve ThornDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.ORCID 0000-0002-9962-9356
Juan Fernández-TajesDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.ORCID 0000-0003-1515-2421
Kitty SherwoodDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.ORCID 0009-0007-4055-607X
Güler GülCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.ORCID 0009-0008-5057-4957
Joost ScheffersDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK.
Anna FrangouBig Data Institute, University of Oxford, Li Ka Shing Centre for Health Information and Discovery, Oxford, OX3 7LF, UK.ORCID 0000-0001-6990-2756
Ben KinnersleyDepartment of Oncology, UCL Cancer Institute, University College London, Paul O'Gorman Building, Huntley Street, London, WC1E 6DD, UK.ORCID 0000-0003-1783-6296
Ioannis KafetzopoulosCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.ORCID 0000-0001-5948-3455
Duncan SproulCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.ORCID 0000-0001-6168-4563
Sara GalavottiInstitute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.ORCID 0000-0002-1240-0963
Claire PallesInstitute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK.ORCID 0000-0002-9670-2263
Andreas J GruberDepartment of Biology, University of Konstanz, Konstanz, Germany.ORCID 0000-0001-7664-4257
David N ChurchCentre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.ORCID 0000-0002-4617-962X
Ian TomlinsonDepartment of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK. ian.tomlinson@oncology.ox.ac.uk.ORCID 0000-0003-3037-1470

Funding

Cancer Research UK CA6199/A27327Wellcome Trust 210804/B/18/Z
6 · The paper itself

Abstract

backgroundSingle base substitution (SBS) mutations, particularly C > T and T > C, are increased owing to unrepaired DNA replication errors in mismatch repair-deficient (MMRd) cancers. Excess CpG > TpG mutations have been reported in MMRd cancers defective in mismatch detection (dMutSα), but not in mismatch correction (dMutLα). Somatic CpG > TpG mutations conventionally result from unrepaired spontaneous deamination of 5'-methylcytosine throughout the cell cycle, causing T:G mismatches and signature SBS1. It has been proposed that MutSα detects those mismatches, prior to error correction by base excision repair (BER). However, other evidence appears inconsistent with that hypothesis: for example, MutSα is specifically expressed in S/G

methodsWe analysed mutation spectra and COSMIC mutation signatures in whole-genome sequencing data from 1803 colorectal cancers (164 dMutLα, 20 dMutSα) and 596 endometrial cancers (103 dMutLα, 9 dMutSα) from the UK 100,000 Genomes Project. We mapped each C > T mutation to its genomic features, including normal DNA methylation state, replication timing, transcription strand, and replication strand, to investigate the mechanism(s) by which these mutations arise.

resultsWe confirmed that dMutSα tumours specifically had higher CpG > TpG burdens than dMutLα tumours. We could fully reconstitute the observed dMutSα CpG > TpG mutation spectrum by adding CpG > TpG mutations in proportion to their SBS1 activity to the dMutLα spectrum. However, other evidence indicated that the SBS1 excess in dMutSα cancers did not come from 5'-methylcytosine deamination alone: non-CpG C > T mutations were also increased in dMutSα cancers; and, in contrast to tumours deficient in BER, CpG > TpG mutations were biased to the leading DNA replication strand, at similar levels in dMutSα and dMutLα cancers, suggesting an origin in DNA replication. Other substitution mutations usually corrected by BER were not increased in dMutSα tumours.

conclusionsThere is a CpG > TpG and SBS1 excess specific to dMutSα MMRd tumours, consistent with previous reports, and we find a general increase in somatic C > T mutations. Contrary to some other studies, the similar leading replication strand bias in both dMutSα and dMutLα tumours indicates that at least some of the excess CpG > TpG mutations arise via DNA replication errors, and not primarily via the replication-independent deamination of 5'-methylcytosine.

Indexed as

Colorectal NeoplasmsCpG IslandsDNA Mismatch RepairDNA ReplicationEndometrial NeoplasmsMutationNeoplasmsDNA-Binding ProteinsDNA MethylationFemaleHumansDNA-Binding ProteinsColorectal cancerDNA repairMismatch repair deficiencyMutagenesisMutation signatures

Identifiers

PMID40855317
PMCPMC12376743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.